Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
March 14, 2018 17:29 ET
|
Proteostasis Therapeutics, Inc.
14-day Study of PTI-801, Company’s Third Generation Corrector, in CF Patients on Background Orkambi® Enrolling Ahead of Schedule; Results from All Three Cohorts Expected Q2'18 Company Announces...
Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis
March 14, 2018 16:30 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
March 12, 2018 16:05 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
March 07, 2018 07:00 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
February 08, 2018 07:00 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis’ Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe
January 08, 2018 07:00 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 21, 2017 16:50 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis Therapeutics Prices Public Offering of Common Stock
December 13, 2017 20:31 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock
December 12, 2017 16:02 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis
December 11, 2017 16:21 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...